APOLLO(Aromatase Inhibitor Patient cOmpLiance Program With qoL Questionaire)

Inclusion Criteria

• •Provision of written informed consent
• •Patients with early breast cancer who are scheduled to receive first-line adjuvant endocrine therapy with aromatase inhibitor under the routine clinical practice
• •Histologically or cytologically proven to be HR+(ER or PR +)
• •Postmenopausal woman, defined as a woman fulfilling any of the following criteria(by the local guideline):
• •* Age \>= 50 years
• •* Age \< 50 years with amenorrhoea \> 12 months and an intact uterus
• •* FSH levels within postmenopausal range (over 30-40 IU/ml), or
• •* Having undergone a bilateral oophorectomy.
• •* No other concomitant endocrine therapy such as estrogen therapy or selective estrogen receptor modulators